Phaseline

Targets › MYB

MYB (Transcriptional activator Myb): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Jul 2027.

Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells. (UniProt, P10242)

Open in Phaseline: the race on MYB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Remix TherapeuticsREM-422
MYB mRNA degrader
MYBPhase 1Myelodysplastic Syndromes; Adenoid Cystic CarcinomaJul 2027
Rgenta TherapeuticsRGT-61159
MYB inhibitor
MYBPhase 1Adenoid Cystic CarcinomaDec 2027

Conditions

Adenoid Cystic Carcinoma (2) Myelodysplastic Syndromes (1)

Modalities

small molecule (2)

Companies

Remix Therapeutics (1) Rgenta Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.